RYTM
Rhythm Pharmaceuticals, Inc.
Stock
$92.83−0.58 (−0.62%)Close Oct 2, 2026
Cash flow statement
| Line | Last 12 months | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | −$105M | −$116M | −$114M | −$136M | −$173M | −$146M | −$122M | −$123M | −$62M | −$29M | −$23M | −$7.0M |
| Capital expenditures | — | $953K | $0 | $47K | $281K | $434K | $214K | $3.4M | $722K | $133K | $1.1M | $17K |
| Free cash flow | — | −$117M | −$114M | −$136M | −$174M | −$146M | −$122M | −$126M | −$63M | −$30M | −$24M | −$7.0M |
| Stock-based compensation | $87M | $67M | $40M | $33M | $20M | $21M | $17M | $12M | $6.4M | $2.3M | $1.2M | $298K |
| Free cash flow margin | — | −61.5% | −87.5% | −175.9% | −734.9% | −4,642.9% | — | — | — | — | — | — |